A lot of medicines are not there to cure diseases. That's fine - drugs that keep people alive who wouldn't otherwise be alive are useful. What I object to is the drug companies' advertising, which you see everywhere in the U.S., which claims that they are curing diseases when they're not.
A vigorous and profitable drug industry is not a problem to be solved but a goal to be encouraged.
If tomorrow the Chinese decide not to supply the world with raw materials, the pharma industry would collapse.
Donald Trump is a dream for business people like me. I think Trump's going to make pharma great again.
Pharma companies don't have a direct relationship with consumers, so they're always subjects.
The cost of prescription drugs in this country is far, far higher than in any other country. You may recall that Donald Trump as a candidate for president talked about how he was going to take on the pharmaceutical industry and it was going to lower prescription drug costs.
Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India.
I believe the pharma company of the future isn't going to be old-school.
I've said all along that we're building Axovant as a lasting company for the long run, not to hand over that upside to a pharma company in the future.
In the pharma space, we have been growing both organically as well as through acquisitions.
Analysts estimate that emerging markets are expected to drive 90 percent of the world's pharmaceutical market growth, and differentiated products will be important to this growth.
The pharma industry is one of the few industries that comes up every year and brags about how much worse they got - like, now it costs $2 billion to make a drug, and it was a billion 5 years ago.
In pharma, we continuously look for acquisitions... if it makes strategic sense and if there is any value.